AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 271 min read$CLBT

Hogan Thomas E. sold $286K of CLBT

Hogan Thomas E. sold 25,299 shares of Cellebrite DI Ltd. (CLBT) at $11.29 ($0.29M total) on 2026-08-25.

Original reporting
SEC EDGAR · Hogan Thomas E.
Published Aug 27, 2026, 10:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
medium confidence
Mentioned
$CLBT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially, but traders monitoring insider activity may adjust short positions.

02

Market read

Primary insider sale filing; low immediate trading relevance.

03

What to watch

Insider may be diversifying; overall company fundamentals unchanged.

Relevance 4/10Novelty 5/10Timing: post-market filing on 2026-08-27

Background

Cellebrite DI Ltd. provides digital intelligence solutions; insider transactions are regularly disclosed via Form 4.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

Form 4 filing shows insider sold 25,299 shares for $285,712, reducing holdings to 765,249.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Sale represents ~3.3% of insider's remaining stake; market may view as minor signal.

Market effects

Sector

Minimal impact on cybersecurity sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a negative signal.

Key entities

  • company
    Cellebrite DI Ltd.

    Cybersecurity and digital forensics firm listed on Nasdaq under CLBT.

  • insider
    Hogan Thomas E.

    Officer/director who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLBT insider trading history →

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min